# US 2026/0265777 A1 · Expression construct

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0265777 A1
- Document ID: US20260265777A1
- Status: Published application
- Kind: A1
- Application number: 19/167,674
- Filed: 2024-03-22
- Published: 2026-09-10
- Earliest claimed: 2023-03-22
- Assignees: Lentitek Ltd
- Applicants: Lentitek Ltd
- Inventors: Adam Inche; Leif Anderson
- Web page: https://patentgrep.com/patent/US20260265777A1

## CPC

- C12N 15/86: Viral vectors
- C07K 14/005: from viruses
- C07K 14/43595: {from coelenteratae, e.g. medusae}
- C12N 15/85: for animal cells
- C12N 2740/13022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/15052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16045: Special targeting system for viral vectors
- C12N 2740/16052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2760/18422: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2830/00: Vector systems having a special element relevant for transcription
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure relates to constructs, especially lentivral constructs for use in an expression system for cell and/or gene therapy applications. The constructs include a viral genome, the expression of which is controlled by an RNA polymerase I promoter.

## Claims

### Claim 1

A lentiviral genome construct comprising a lentiviral genome and a RNA polymerase I promoter, wherein expression of the lentiviral genome is under control of the RNA Polymerase I promoter.

### Claim 2 (depends on 1)

The lentiviral genome construct of claim 1, wherein the construct further comprises a Pol I termination signal.

### Claim 3 (depends on 1)

The lentiviral genome construct of claim 1, wherein the construct further comprises a 5′ long terminal repeat (5′ LTR) and/or a 3′ long terminal repeat (3′ LTR) and wherein the 5′ LTR and/or 3′ LTR may be self-inactivating.

### Claim 4 (depends on 1)

The lentiviral genome construct of claim 1, wherein the 5′ LTR is positioned or located downstream of the RNA polymerase I (Pol I) promoter and the 3′ LTR is positioned or located upstream of the Pol I termination signal.

### Claim 5 (depends on 1)

The lentiviral genome construct of claim 1, wherein the construct further comprises an insert, which insert is flanked by said 5′ and 3′ long terminal repeats.

### Claim 6 (depends on 1)

The lentiviral genome construct of claim 1, further comprising a transgene.

### Claim 7 (depends on 1)

A lentiviral genome construct according to claim 1 comprising:
(i) a RNA polymerase I (Pol I) promoter;
(ii) a Pol I termination signal;
(iii) a 5′ long terminal repeat (5′ LTR);
(iv) a 3′ long terminal repeat (3′ LTR); and
(v) an insert, optionally comprising a transgene, located or disposed between the 5′ and 3′ long terminal repeats;
wherein, the 5′ LTR is positioned or located downstream of the RNA polymerase I (Pol I) promoter and the 3′ LTR is positioned or located upstream of the Pol I termination signal and wherein the 5′ LTR and/or 3′ LTR may be self-inactivating.

### Claim 8

A construct for use in an expression system, wherein the construct comprises:
an insert flanked by a 5′ long terminal repeat (5′ LTR) and a 3′ long terminal repeat (3′ LTR), wherein the 5′ LTR is downstream of an RNA polymerase I (Pol I) promoter and the 3′ LTR is upstream of a Pol I termination signal, wherein said insert comprises a transgene and wherein the 5′ LTR and/or 3′ LTR may be self-inactivating.

### Claim 9 (depends on 8)

The construct for use of claim 8, wherein the expression system is for use in producing a recombinant retrovirus,
said insert optionally further comprising a posttranscriptional response element downstream of said transgene;
and further optionally, said insert comprising a retroviral packaging element and/or one or more nuclear export component(s) upstream of said transgene.

### Claim 10 (depends on 8)

The construct for use according to claim 8, wherein the transgene of said insert comprises a nucleic acid sequence encoding one or more gene(s) of interest.

### Claim 11 (depends on 8)

The construct for use according to claim 8, wherein the insert further comprises one or more additional promoter(s) for the expression of the one or more gene(s) of interest.

### Claim 12 (depends on 8)

The construct for use according to claim 8, wherein the construct is inserted into a vector.

### Claim 13 (depends on 12)

The construct for use according to claim 12, wherein the vector is a plasmid.

### Claim 14 (depends on 8)

The construct for use according to claim 8, wherein the Pol I promoter is derived from a mammalian Pol I promoter sequence.

### Claim 15 (depends on 8)

The construct for use according to claim 8, wherein the one or more additional promoter(s) for the expression of one or more gene(s) of interest comprises an RNA polymerase II promoter.

### Claim 16 (depends on 15)

The construct for use according to claim 15, wherein the RNA polymerase II promoter is a CMV, RSV, SV40, EFS (EF1a short), Ubc promoter, or SFFV promoter.

### Claim 17 (depends on 8)

The construct for use according to claim 8, wherein the expression system is for use in producing a recombinant lentivirus.

### Claim 18 (depends on 17)

The construct for use according to claim 17, wherein the recombinant retrovirus is a non-replicating recombinant retrovirus or the recombinant lentivirus is a non-replicating recombinant lentivirus.

### Claim 19 (depends on 8)

The construct according to claim 8, wherein the system-optionally further comprises one or more vector(s) comprising:
one or more viral genome packaging component(s);
one or more viral envelope protein(s);
one or more nuclear export element(s); and/or
one or more stabilising motif(s).

### Claim 20 (depends on 19)

The construct of claim 19, wherein the one or more viral genome packaging component(s) comprises Gag, Pol and/or Rev.

### Claim 21 (depends on 19)

The construct of claim 19, wherein the one or more viral envelope protein(s) comprises VSV-G, murine leukemia virus (MULV), the gibbon ape leukemia virus (GALV), the feline endogenous RD114 retrovirus, Moloney MULV 4070A, Moloney MULV strain 10A1, rabies virus glycoprotein, and/or the measles virus hemagglutinin and fusion glycoprotein.

### Claim 22 (depends on 19)

The construct of claim 19, wherein the one or more nuclear export element(s) comprises Rev response element (RRE).

### Claim at position 23

23-32. (canceled)

### Claim 33 (depends on 1)

A method for producing a recombinant retrovirus, wherein the method comprises transfecting a host cell by contacting the said host cell with the construct of claim 1, and one or more vector(s) encoding one or more additional viral components; culturing the host cell under conditions in which the recombinant retroviral vector particles are produced; and isolating said recombinant retroviral vector particles.

### Claim 34 (depends on 33)

The method of claim 33, wherein the recombinant retrovirus is a recombinant lentivirus.

### Claim 35

(canceled)

### Claim 36 (depends on 33)

The method of claim 33, wherein the one or more additional viral components are selected from: (i) one or more packaging component(s); and/or (ii) one or more envelope protein(s);

### Claim 37 (depends on 33)

The method of claim 33, wherein the one or more packaging component(s) comprises Gag, Pol and/or Rev, and the envelope protein comprises VSV-G, murine leukemia virus (MULV), the gibbon ape leukemia virus (GALV), the feline endogenous RD114 retrovirus, Moloney MULV 4070A, Moloney MULV strain 10A1, rabies virus glycoprotein, and/or the measles virus hemagglutinin and fusion glycoprotein.

### Claim 38

(canceled)

### Claim 39 (depends on 33)

The method of claim 33, wherein the method further comprising selecting cell clones in which the various lentiviral genetic elements have stably integrated into the cell's genome.

### Claim 40

(canceled)
